Rekah Pharmaceutical Industry Ltd (REKA) - Net Assets
Based on the latest financial reports, Rekah Pharmaceutical Industry Ltd (REKA) has net assets worth ILA144.21 Million ILA (≈ $386.62K USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (ILA423.68 Million ≈ $1.14 Million USD) and total liabilities (ILA279.47 Million ≈ $749.25K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Rekah Pharmaceutical Industry Ltd liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ILA144.21 Million |
| % of Total Assets | 34.04% |
| Annual Growth Rate | 5.29% |
| 5-Year Change | -16.67% |
| 10-Year Change | 36.23% |
| Growth Volatility | 16.43 |
Rekah Pharmaceutical Industry Ltd - Net Assets Trend (2004–2025)
This chart illustrates how Rekah Pharmaceutical Industry Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Rekah Pharmaceutical Industry Ltd asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for Rekah Pharmaceutical Industry Ltd (2004–2025)
The table below shows the annual net assets of Rekah Pharmaceutical Industry Ltd from 2004 to 2025. For live valuation and market cap data, see REKA stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ILA144.21 Million ≈ $386.62K |
-10.97% |
| 2024-12-31 | ILA161.98 Million ≈ $434.25K |
+4.11% |
| 2023-12-31 | ILA155.59 Million ≈ $417.12K |
-4.01% |
| 2022-12-31 | ILA162.08 Million ≈ $434.53K |
-6.35% |
| 2021-12-31 | ILA173.06 Million ≈ $463.98K |
+4.51% |
| 2020-12-31 | ILA165.59 Million ≈ $443.94K |
+6.68% |
| 2019-12-31 | ILA155.22 Million ≈ $416.13K |
+3.03% |
| 2018-12-31 | ILA150.66 Million ≈ $403.91K |
+4.17% |
| 2017-12-31 | ILA144.62 Million ≈ $387.73K |
+36.62% |
| 2016-12-31 | ILA105.86 Million ≈ $283.81K |
-14.39% |
| 2015-12-31 | ILA123.66 Million ≈ $331.52K |
+60.47% |
| 2014-12-31 | ILA77.06 Million ≈ $206.59K |
-3.09% |
| 2013-12-31 | ILA79.51 Million ≈ $213.17K |
+11.73% |
| 2012-12-31 | ILA71.17 Million ≈ $190.79K |
+11.19% |
| 2011-12-31 | ILA64.00 Million ≈ $171.59K |
+0.35% |
| 2010-12-31 | ILA63.78 Million ≈ $171.00K |
-0.58% |
| 2009-12-31 | ILA64.15 Million ≈ $171.99K |
+9.43% |
| 2008-12-31 | ILA58.62 Million ≈ $157.17K |
-12.63% |
| 2007-12-31 | ILA67.10 Million ≈ $179.88K |
+9.04% |
| 2006-12-31 | ILA61.54 Million ≈ $164.98K |
+4.57% |
| 2005-12-31 | ILA58.85 Million ≈ $157.77K |
+20.44% |
| 2004-12-31 | ILA48.86 Million ≈ $131.00K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Rekah Pharmaceutical Industry Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 86.1% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ILA3.39 Million | 2.35% |
| Common Stock | ILA13.64 Million | 9.46% |
| Other Comprehensive Income | ILA1.03 Million | 0.71% |
| Other Components | ILA126.11 Million | 87.48% |
| Total Equity | ILA144.16 Million | 100.00% |
Rekah Pharmaceutical Industry Ltd Competitors by Market Cap
The table below lists competitors of Rekah Pharmaceutical Industry Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Tourindo Guide Indonesia Pt
JK:PGJO
|
$33.58 Million |
|
Dcon Products Public Company Limited
BK:DCON
|
$33.58 Million |
|
Wellbiotec Co. Ltd.
KO:010600
|
$33.58 Million |
|
Pelayaran Nelly Dwi Putri Tbk
JK:NELY
|
$33.60 Million |
|
FORCS Co.Ltd
KQ:189690
|
$33.56 Million |
|
Sunfar Computer Co Ltd
TWO:6154
|
$33.56 Million |
|
Mabion S.A.
WAR:MAB
|
$33.54 Million |
|
Avonmore Capital & Management Services Limited
NSE:AVONMORE
|
$33.54 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Rekah Pharmaceutical Industry Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 161,928,000 to 144,160,000, a change of -17,768,000 (-11.0%).
- Net loss of 18,074,000 reduced equity.
- Other comprehensive income increased equity by 38,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ILA-18.07 Million | -12.54% |
| Other Comprehensive Income | ILA38.00K | +0.03% |
| Other Changes | ILA268.00K | +0.19% |
| Total Change | ILA- | -10.97% |
Book Value vs Market Value Analysis
This analysis compares Rekah Pharmaceutical Industry Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 86.86x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 84.92x to 86.86x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | ILA12.92 | ILA1097.00 | x |
| 2013-12-31 | ILA14.43 | ILA1097.00 | x |
| 2014-12-31 | ILA13.97 | ILA1097.00 | x |
| 2015-12-31 | ILA14.65 | ILA1097.00 | x |
| 2016-12-31 | ILA10.99 | ILA1097.00 | x |
| 2017-12-31 | ILA15.11 | ILA1097.00 | x |
| 2018-12-31 | ILA13.86 | ILA1097.00 | x |
| 2019-12-31 | ILA13.59 | ILA1097.00 | x |
| 2020-12-31 | ILA14.50 | ILA1097.00 | x |
| 2021-12-31 | ILA15.16 | ILA1097.00 | x |
| 2022-12-31 | ILA14.19 | ILA1097.00 | x |
| 2023-12-31 | ILA13.63 | ILA1097.00 | x |
| 2024-12-31 | ILA13.51 | ILA1097.00 | x |
| 2025-12-31 | ILA12.63 | ILA1097.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Rekah Pharmaceutical Industry Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -12.54%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -6.00%
- • Asset Turnover: 0.71x
- • Equity Multiplier: 2.94x
- Recent ROE (-12.54%) is below the historical average (2.35%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | 18.30% | 3.48% | 1.25x | 4.19x | ILA4.00 Million |
| 2005 | 11.15% | 2.45% | 0.98x | 4.61x | ILA668.10K |
| 2006 | 9.52% | 2.01% | 0.96x | 4.92x | ILA-286.90K |
| 2007 | 6.75% | 1.55% | 0.95x | 4.58x | ILA-2.13 Million |
| 2009 | 8.28% | 1.96% | 0.94x | 4.48x | ILA-1.07 Million |
| 2010 | 0.61% | 0.15% | 0.91x | 4.57x | ILA-5.92 Million |
| 2011 | 0.85% | 0.21% | 0.89x | 4.52x | ILA-5.82 Million |
| 2012 | 10.49% | 2.74% | 0.91x | 4.22x | ILA344.20K |
| 2013 | 10.55% | 3.08% | 0.89x | 3.84x | ILA433.40K |
| 2014 | -0.66% | -0.23% | 0.70x | 4.06x | ILA-8.14 Million |
| 2015 | -3.59% | -1.68% | 0.81x | 2.63x | ILA-16.71 Million |
| 2016 | -10.43% | -5.04% | 0.68x | 3.06x | ILA-21.55 Million |
| 2017 | -15.50% | -10.80% | 0.71x | 2.03x | ILA-36.98 Million |
| 2018 | 4.64% | 3.38% | 0.69x | 1.98x | ILA-8.11 Million |
| 2019 | 2.49% | 1.97% | 0.54x | 2.37x | ILA-11.65 Million |
| 2020 | 6.52% | 4.07% | 0.63x | 2.54x | ILA-5.76 Million |
| 2021 | 3.83% | 2.51% | 0.60x | 2.53x | ILA-10.68 Million |
| 2022 | -1.26% | -0.70% | 0.65x | 2.77x | ILA-18.25 Million |
| 2023 | -4.44% | -2.15% | 0.66x | 3.12x | ILA-22.46 Million |
| 2024 | 3.83% | 1.93% | 0.72x | 2.76x | ILA-9.99 Million |
| 2025 | -12.54% | -6.00% | 0.71x | 2.94x | ILA-32.49 Million |
Industry Comparison
This section compares Rekah Pharmaceutical Industry Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $522,087,701
- Average return on equity (ROE) among peers: -55.54%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Rekah Pharmaceutical Industry Ltd (REKA) | ILA144.21 Million | 18.30% | 1.94x | $33.57 Million |
| Canzon Israel Ltd (CNZN) | $12.27 Million | -25.33% | 0.07x | $2.08 Million |
| Intercure (INCR) | $697.01K | -544.18% | 2.79x | $36.65 Million |
| Intelicanna Ltd (INTL) | $4.41 Billion | 12.46% | 8.24x | $9.32 Million |
| Kamada (KMDA) | $135.32 Million | 16.44% | 0.28x | $354.44 Million |
| Nextage Therapeutics Ltd (NXTG) | $-426.00K | 0.00% | 0.00x | $5.79 Million |
| Seach Medical Group Ltd (SEMG) | $79.25 Million | 15.10% | 0.17x | $22.97 Million |
| Teva Pharmaceutical Industries Ltd (TEVA) | $57.80 Million | 25.61% | 1.47x | $1.23 Billion |
| Together Startup Network Ltd (TGTR) | $-187.00K | 0.00% | 0.00x | $9.28 Million |
| Tikun Olam Cannbit Pharmaceuticals Ltd (TKUN) | $-492.00K | 0.00% | 0.00x | $28.21 Million |
About Rekah Pharmaceutical Industry Ltd
Rekah Pharmaceutical Industry Ltd. engages in the manufacture, marketing, sale, and distribution of pharmaceuticals, cosmetics, vitamins and nutritional supplements, and medical devices in Israel. The company offers steroids, antibiotics, and ophthalmic products, as well as dermo-cosmetics products. Its portfolio of products comprise Rx and OTC drugs, and medical devices used in various therapeut… Read more